Soquelitinib for adults with hidradenitis suppurativa
Treatments studied
Part of Infections, Skin clinical trials.
This trial tests a new oral medication, soquelitinib, in adults with moderate-to-severe hidradenitis suppurativa (HS), the skin condition that causes painful lumps and tunnels. Soquelitinib works by calming the immune system to reduce inflammation. The study aims to see if it is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You must have had moderate-to-severe HS for at least 1 year.
- You must have at least 5 inflammatory lesions (abscesses or painful nodules), including at least 2 that you can feel.
- You must have HS in at least 2 different body areas (e.g., both armpits), with at least one area at a more advanced stage (Hurley stage II or III).
- You must have tried antibiotics and they did not work well enough, you could not tolerate them, or you cannot take them for medical reasons.
- You must be willing to have skin biopsies (small samples of skin taken for testing).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an oral medication called povorcitinib for adolescents aged 12–17 with moderate to severe hidradenitis suppurativa (HS) that hasn't improved with standard treatments like antibiotics. It aims to see how well the drug works and if it's safe.
This study tests a drug called secukinumab (a type of biologic that targets inflammation) for people with moderate to severe hidradenitis suppurativa (HS). It may be an option if you have tried other treatments and they didn't work well.
This trial tests a new medication called CIT-013 for people with moderate to severe hidradenitis suppurativa (HS) who have not had enough relief from oral antibiotics. The goal is to see if this treatment can reduce painful bumps and abscesses.
This trial tests a new medicine called SCT650C for people with moderate to severe hidradenitis suppurativa (HS). The goal is to see if it can reduce painful bumps and abscesses better than current treatments.
This trial is testing an experimental tablet called LT-002-158 in adults with moderate to severe hidradenitis suppurativa (HS) that hasn't improved enough with standard treatments. The goal is to see if it's safe and helps reduce painful lumps and abscesses.
This study tests if a drug called secukinumab (a self-injected biologic) is safe and effective for adults with moderate-to-severe hidradenitis suppurativa (HS) in China. It may help reduce the number of painful HS lesions.
Hear when a new Hidradenitis Suppurativa (HS) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.